Mesoblast, JCR Expand the Use of Mesenchymal Stem Cells for Treating Newborns with HIE
Mesoblast announced it has expanded its partnership with JCR Pharmaceuticals in Japan to include the use of mesenchymal stem cells (MSCs) for treating newborns who have neonatal hypoxic ischemic encephalopathy (HIE), a condition in which an unborn baby experiences shortage of oxygen supply to the brain during…